<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/18/2022 7:13:04 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 52379515-3db3-44b4-b8a5-7b2cfcc42141 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:nrxp="http://nrxphar.com/20220315" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityCentralIndexKey" id="Tc_WjXvKHnc5k-9SNIhRDS_wg_2_1">0001719406</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:AmendmentFlag" id="Tc_Wqf3jaR6NUq0TxnKsd3O7w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nrxp-20220315.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_WarrantsToPurchaseOneShareOfCommonStockMember_9uvIOmO6q0uXrYtVG_ToYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:WarrantsToPurchaseOneShareOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_CommonStockParValue0.001PerShareMember_pIIMqwwpAEmAo_IKYX-OJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:CommonStockParValue0.001PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:8.62pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 7.7pt;"><span style="font-size:3pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.3pt 0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p><div style="margin-bottom:0.15pt;padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9b586346_d08d_4151_b1ec_e7adcec3eeff"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.15pt 0pt;"><b style="font-size:14.5pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.64pt 0pt;"><b style="font-size:14.5pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4.65pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14.5pt;text-align:center;margin:0pt 0pt 5.44pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:DocumentType" id="Narr_GO3NaBZBCkqWXDR3lu713A"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.4pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4.84pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.65pt 0pt;"><span style="font-size:7.5pt;">Date of Report (Date of earliest event reported) </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:DocumentPeriodEndDate" id="Narr_NZgBoFP_906qPq5oTlrHFA"><b style="font-size:7.5pt;font-weight:bold;">March 15, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14.5pt;text-align:center;margin:0pt 0pt 0.64pt 0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityRegistrantName" id="Narr_Sx8TOv7AoUqP9glsI3KC_A"><b style="font-weight:bold;">NRX PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_adfaad1e_5179_4a36_9dbf_2cddbd17a631"></a><a id="Tc_APPZS5sMbU22Hdku1L35qQ_2_0"></a><a id="Tc_TYTmj2t5hUuoOj3dihuKpw_2_1"></a><a id="Tc_NT4xgBd8wkWL_IXdz2HvRQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityIncorporationStateCountryCode" id="Tc_5rWJalY3sk-fiF4jC8PTbg_1_0"><b style="font-size:7.5pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityFileNumber" id="Tc_dLJm1YTeCka4E8y_HuE1SA_1_1"><b style="font-size:7.5pt;font-weight:bold;">001-38302</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityTaxIdentificationNumber" id="Tc_rHKZ9nO9nkOjRD3J2m5qww_1_2"><b style="font-size:7.5pt;font-weight:bold;">82-2844431</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">(State or other jurisdiction of incorporation)</span></p></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">(Commission File Number)</span></p></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">(I.R.S. Employer Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_37178aba_a76d_4454_8b48_290320006206"></a><a id="Tc_mUqq1SJmKUO6YdsYZk4v7w_1_0"></a><a id="Tc_lkczqRkmDkqzmrXilyacTA_2_0"></a><a id="Tc_THlFyNMG6UagAbJ4MY2XHg_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityAddressAddressLine1" id="Narr_2cqBy7wkGUmpDbz8yS8_VQ"><b style="font-size:7.5pt;font-weight:bold;">1201 Orange Street</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityAddressAddressLine2" id="Narr_WFqZa7BKh0Gll4UOnwZ_TA"><b style="font-size:7.5pt;font-weight:bold;">Suite 600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityAddressCityOrTown" id="Narr_0X54l2a-AkuBPdo6w_cBMg"><b style="font-size:7.5pt;font-weight:bold;">Wilmington</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityAddressStateOrProvince" id="Narr_iEQNgDxdDEeTcq_w3-W45Q"><b style="font-size:7.5pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityAddressPostalZipCode" id="Tc_6GOTTOC4AEeUy4qguVOnoQ_1_1"><b style="font-size:7.5pt;font-weight:bold;">19801</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">(Address of principal executive offices)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">(Zip Code)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.19pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:CityAreaCode" id="Narr_7ZpahxsyC0y1VQjSvzKl9g"><b style="font-size:7.5pt;font-weight:bold;">484</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:LocalPhoneNumber" id="Narr_a-m_xBTVh0aSRcqWyXmd3w"><b style="font-size:7.5pt;font-weight:bold;">254-6134</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 5.15pt 0pt;"><span style="font-size:7.5pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.4pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.8pt 0pt;"><span style="font-size:7.5pt;">(Former name or former address, if changed since last report.)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;margin-bottom:0.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.5pt 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:WrittenCommunications" id="Narr_Dl66NINW0UiMguiU9IEO5g"><span style="font-family:'Arial Unicode MS';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:SolicitingMaterial" id="Narr_sAMYR8FysUOP1MTOJdGSwg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:PreCommencementTenderOffer" id="Narr_Pr4V-2JVZUeVD9NoFap9Qw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:PreCommencementIssuerTenderOffer" id="Narr_GFFRmvkcoEGfbz8F6gsRcA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_2a535fb6_2a77_46e3_9877_15f6ff740562"></a><a id="Tc_CE2_x8kCIkeu3a1h3wmHqQ_1_0"></a><a id="Tc_HHWWm9b_qE-ReebtLlUx9A_1_2"></a><a id="Tc_3BurKS7fKE65RIx9hxBfyA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:28.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">registered</b></p></td></tr><tr><td style="vertical-align:top;width:35.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_CommonStockParValue0.001PerShareMember_pIIMqwwpAEmAo_IKYX-OJA" name="dei:Security12gTitle" id="Tc_B0cHtESef0Sx0I4Ni64ipA_2_0"><span style="font-size:8pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_CommonStockParValue0.001PerShareMember_pIIMqwwpAEmAo_IKYX-OJA" name="dei:TradingSymbol" id="Tc_NIjUpWvzAUW9WQGhnbg22g_2_2"><span style="font-size:8pt;">NRXP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_CommonStockParValue0.001PerShareMember_pIIMqwwpAEmAo_IKYX-OJA" name="dei:SecurityExchangeName" id="Tc_dfYXMi5lJEGAAD35Eu4Ldg_2_4"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:35.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_WarrantsToPurchaseOneShareOfCommonStockMember_9uvIOmO6q0uXrYtVG_ToYg" name="dei:Security12gTitle" id="Tc_jEEOIgmcqUe6ZCVzcHlolg_3_0"><span style="font-size:8pt;">Warrants to purchase one share of Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_WarrantsToPurchaseOneShareOfCommonStockMember_9uvIOmO6q0uXrYtVG_ToYg" name="dei:TradingSymbol" id="Tc_aO3hoesq7kKm-eZ_yrG-9w_3_2"><span style="font-size:8pt;">NRXPW</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_StatementClassOfStockAxis_nrxp_WarrantsToPurchaseOneShareOfCommonStockMember_9uvIOmO6q0uXrYtVG_ToYg" name="dei:SecurityExchangeName" id="Tc_yX5cb9VD-EOzeAZEXRBlcA_3_4"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 4.84pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5.19pt 0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityEmergingGrowthCompany" id="Narr_mkBwVtVbyUypGEEKREmf6A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.4pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_15_2022_To_3_15_2022_ruuqlMt_9kWcUyvpTjNOMg" name="dei:EntityExTransitionPeriod" id="Narr_TMqi1bvEaE-V6v15L11I9A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><div style="margin-bottom:0.4pt;padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:justify;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.4pt 8.3pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt 0pt 0.4pt 8.3pt;"><span style="font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_6edbd9a3_1d6f_4c61_a216_9e199461bf8f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 8.3pt;"><span style="display:inline-block;text-indent:0pt;width:57.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 5.02</b></span><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 8.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 8.3pt;"><b style="font-weight:bold;">Appointment of Mr. Ira Strassberg as Chief Financial Officer and Treasurer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 8.3pt;">On March 15, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the &#8220;Company&#8221;) appointed Mr. Ira Strassberg, 55, to serve as Chief Financial Officer (CFO) and Treasurer of the Company effective immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 8.3pt;">Mr. Strassberg has been serving as a financial consultant to the Company since August 2021. Prior to joining the Company, Mr. Strassberg simultaneously served as Senior Managing Director and deputy CFO of Cantor Fitzgerald, L.P. from January 2018 to June 2021, and as CFO of Cantor Commercial Real Estate Company, L.P. from October 2014 to June 2021. &#160;His prior positions include serving on the Board of Directors and Audit Committee of Continental Building Products, Inc., as CFO of Berkeley Point Capital, Fannie Mae&#8217;s multifamily business division and Walker &amp; Dunlop. &#160;He also held senior financial leadership positions at Freddie Mac in addition to a 14-year career in both audit and consulting at KPMG. Mr. Strassberg is a certified public accountant, certified management accountant and a chartered global management accountant and holds a B.S. in Accounting from Georgetown University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 8.3pt;">Mr. Strassberg has no familial relationships with any executive officer or director of the Company. There have been no transactions in which the Company has participated and in which Mr. Strassberg had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:8.3pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employment Arrangements with Mr. Strassberg</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 8.65pt;">On March 15, 2022, Mr. Strassberg entered into an employment agreement with the Company (the &#8220;<span style="font-style:italic;font-weight:bold;">Agreement</span>&#8221;). The Agreement provides for an aggregate monthly payment of $33,333.33 to Mr. Strassberg for total annual payment of approximately $400,000 (the &#8220;<span style="font-style:italic;font-weight:bold;">Base Salary</span>&#8221;) and an annual target bonus payment of $200,000 at the discretion of the Board and upon satisfactory performance of his duties (the &#8220;<span style="font-style:italic;font-weight:bold;">Target Bonus</span>&#8221;). The Agreement also provides for the grant of stock options (the &#8220;<span style="font-style:italic;font-weight:bold;">Options</span>&#8221;) to purchase 425,000 shares of the Company&#8217;s common stock at an exercise price of $3.10 per share (the closing price on the date of grant). The Options vest over a two-year period, subject to Mr. Strassberg&#8217;s continued service with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 8.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 8.3pt;">If Mr. Strassberg is terminated by the Company without &#8220;cause&#8221; or upon a change of control, or he resigns for &#8220;good reason&#8221;, he is entitled to receive severance pay equal to the sum of the Base Salary, at the rate in effect on the date of termination, from the date of termination through the one-year anniversary thereof, and a prorated Target Bonus through the date of termination. &#160;In addition, all unvested Options will vest and become fully exercisable. &#160;Mr. Strassberg will also be entitled to customary indemnification and directors and officers insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 8.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 8.3pt;">The foregoing summary of the material terms of the Agreement is subject to the full and complete terms of the Agreement, <span style="color:#201f1e;">which the Company expects to file an exhibit to its periodic report covering the effective date of his employment</span>.</p><a id="_2b6f7ef8_182d_4b83_9d4a_eea1d32815bc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 8.3pt;"><span style="display:inline-block;text-indent:0pt;width:57.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 8.01</b></span><b style="font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 5pt 8.3pt;">On March 18, 2022, the Company issued a press release announcing the appointment of Ira Strassberg as Chief Financial Officer and Treasurer. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 8.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_b080b809_083d_4122_bc13_37dc39915925"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 8.3pt;"><span style="display:inline-block;text-indent:0pt;width:57.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 5pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><i style="font-style:italic;">(d) Exhibits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:13.89%;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:82.38%;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:82.38%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:middle;width:13.89%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.38%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrxp-20220315xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release, dated March 18, 2022.</span></a></p></td></tr><tr><td style="vertical-align:middle;width:13.89%;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.38%;margin:0pt;padding:0.25pt 5.65pt 0.25pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_bfdbd5c6_781a_4323_ac54_56d2cbe078d0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.8pt;margin:0pt 0pt 0pt 8.3pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.8pt;margin:0pt 0pt 0pt 8.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NRX PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;">Date:</p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.65pt;">March 18, 2022</p></td><td style="vertical-align:top;width:6.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:39.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.7pt;">/s/ Alessandra Daigneault</p></td></tr><tr><td style="vertical-align:top;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:39.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.7pt;">Alessandra Daigneault</p></td></tr><tr><td style="vertical-align:top;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.7pt;">General Counsel and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6.09pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "nrxp-20220315x8k.htm", "description": "8-K", "secsgml_size_bytes": 48465}]
{"company-data": {"conformed-name": "NRX Pharmaceuticals, Inc.", "cik": "0001719406", "assigned-sic": "2834", "irs-number": "822844431", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-38302", "film-number": "22752736"}, "business-address": {"street1": "1201 N. MARKET STREET", "street2": "SUITE 111", "city": "WILMINGTON", "state": "DE", "zip": "19801", "phone": "484-254-6134"}, "mail-address": {"street1": "1201 N. MARKET STREET", "street2": "SUITE 111", "city": "WILMINGTON", "state": "DE", "zip": "19801"}, "former-company": {"former-conformed-name": "Big Rock Partners Acquisition Corp.", "date-changed": "20171012"}}
​
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
March 15, 2022
NRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
​
​
​
​
Delaware
001-38302
82-2844431
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
​
​
​
​
​
1201 Orange Street
,
Suite 600
Wilmington
,
Delaware
19801
(Address of principal executive offices)
(Zip Code)
​
(
484
)
254-6134
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act
​
​
​
​
​
​
​
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.001 per share
​
NRXP
​
The Nasdaq Stock Market LLC
Warrants to purchase one share of Common Stock
​
NRXPW
​
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
​
Appointment of Mr. Ira Strassberg as Chief Financial Officer and Treasurer
On March 15, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the "Company") appointed Mr. Ira Strassberg, 55, to serve as Chief Financial Officer (CFO) and Treasurer of the Company effective immediately.
Mr. Strassberg has been serving as a financial consultant to the Company since August 2021. Prior to joining the Company, Mr. Strassberg simultaneously served as Senior Managing Director and deputy CFO of Cantor Fitzgerald, L.P. from January 2018 to June 2021, and as CFO of Cantor Commercial Real Estate Company, L.P. from October 2014 to June 2021.  His prior positions include serving on the Board of Directors and Audit Committee of Continental Building Products, Inc., as CFO of Berkeley Point Capital, Fannie Mae's multifamily business division and Walker & Dunlop.  He also held senior financial leadership positions at Freddie Mac in addition to a 14-year career in both audit and consulting at KPMG. Mr. Strassberg is a certified public accountant, certified management accountant and a chartered global management accountant and holds a B.S. in Accounting from Georgetown University.
Mr. Strassberg has no familial relationships with any executive officer or director of the Company. There have been no transactions in which the Company has participated and in which Mr. Strassberg had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.
Employment Arrangements with Mr. Strassberg
On March 15, 2022, Mr. Strassberg entered into an employment agreement with the Company (the "
Agreement
"). The Agreement provides for an aggregate monthly payment of $33,333.33 to Mr. Strassberg for total annual payment of approximately $400,000 (the "
Base Salary
") and an annual target bonus payment of $200,000 at the discretion of the Board and upon satisfactory performance of his duties (the "
Target Bonus
"). The Agreement also provides for the grant of stock options (the "
Options
") to purchase 425,000 shares of the Company's common stock at an exercise price of $3.10 per share (the closing price on the date of grant). The Options vest over a two-year period, subject to Mr. Strassberg's continued service with the Company.
​
If Mr. Strassberg is terminated by the Company without "cause" or upon a change of control, or he resigns for "good reason", he is entitled to receive severance pay equal to the sum of the Base Salary, at the rate in effect on the date of termination, from the date of termination through the one-year anniversary thereof, and a prorated Target Bonus through the date of termination.  In addition, all unvested Options will vest and become fully exercisable.  Mr. Strassberg will also be entitled to customary indemnification and directors and officers insurance coverage.
​
The foregoing summary of the material terms of the Agreement is subject to the full and complete terms of the Agreement,
which the Company expects to file an exhibit to its periodic report covering the effective date of his employment
.
Item 8.01
Other Events.
On March 18, 2022, the Company issued a press release announcing the appointment of Ira Strassberg as Chief Financial Officer and Treasurer. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
​
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
​
​
​
​
Exhibit No.
Description
99.1
​
Press release, dated March 18, 2022.
104
​
Cover Page Interactive Data File (embedded within the Inline XBRL document)
​
​
​
SIGNATURE
​
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
​
NRX PHARMACEUTICALS, INC.
​
​
​
Date:
March 18, 2022
By:
/s/ Alessandra Daigneault
​
​
Name:
Alessandra Daigneault
​
​
Title:
General Counsel and Corporate Secretary
​
​
​
​
​